论文部分内容阅读
为探讨血清可溶性白介素一2受体（SIL—2R）在原发性肝癌（PHC）患者肝动脉栓塞化疗（transcatheterarterialchemoembolization，TACE）后的临床意义，分别于术后不同时间检测了15例第1次行TACE和6例反复行TACE术的PHC患者血清SIL—2R水平。结果显示第一次行TACE术的PHC患者治疗前血清SIL—2R水平明显高于正常（P<0．01），经TACE治疗后1周SIL一2R开始下降，2周时最低（P<0．01），但4周时又回复至治疗前水平（P＞0．05）；而多次行TACE术的PHC患者经治疗后2周和4周时仍较低（P<0．01）。提示多次TACE术可提高免疫细胞活性；监测血清SIL—2R水平有助于判断TACE疗效和选择合理的化疗药剂量，也有助于预后的估计。
To investigate the clinical significance of serum soluble interleukin-2 receptor (SIL-2R) in patients with primary liver cancer (PHC) after transcatheter arterial chemoembolization (TACE), 15 patients were tested at different times after operation for the first time. The levels of serum SIL-2R in PHC patients undergoing TACE and 6 repeated TACE were performed. The results showed that the serum SIL-2R levels in PHC patients before the first TACE were significantly higher than normal (P<0.01). SIL-2R began to decrease after 1 week of TACE treatment and was lowest at 2 weeks (P<0). .01), but returned to the pre-treatment level at 4 weeks (P>0.05); PHC patients undergoing multiple TACE were still low at 2 weeks and 4 weeks after treatment (P<0.01). . It is suggested that multiple TACE procedures can improve the activity of immune cells; monitoring serum SIL-2R levels can help to determine the efficacy of TACE and select a reasonable amount of chemotherapeutic agents, but also help to estimate the prognosis.